Design Therapeutics, Inc. Profile Avatar - Palmy Investing

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia…

Biotechnology
US, Carlsbad [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Design Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of DSGN's Analysis
CIK: 1807120 CUSIP: 25056L103 ISIN: US25056L1035 LEI: - UEI: -
Secondary Listings
DSGN has no secondary listings inside our databases.